Key result
Text provides only editorial board and publication information for Seminars in Thrombosis and Hemostasis.
Why the study?
Despite extensive clinical data, several unresolved questions remain regarding the contemporary clinical use of aspirin across various indications and formulations.
This review summarizes the contemporary clinical applications of aspirin, highlighting its established role in secondary cardiovascular prevention and pregnancy, while noting the unfavorable risk-benefit ratio for primary prevention due to bleeding.
No trial data presented; leaves open aspirin's primary prevention role due to bleeding risk.
The ability of aspirin to inhibit platelet aggregation has positioned this agent within the most frequently used drugs worldwide. The aim of this article is to review the contemporary clinical use of aspirin and also to discuss unresolved issues not yet translated into clinical practice. Results from several clinical trials have led to strong guideline recommendations for aspirin use in the acute management and secondary prevention of cardiovascular disease. On the contrary, guidelines regarding aspirin use as primary prevention of cardiovascular disease are almost conservative, supported by recent trials reporting that the bleeding risk outweighs the potential benefits in most patients. In pregnancy, aspirin has proved efficient in preventing preeclampsia and small-for-gestational-age births in women at high risk, and is hence widely recommended in clinical guidelines. Despite the vast amount of clinical data on aspirin, several unresolved questions remain. Randomized trials have reported that aspirin reduces the risk of recurrent venous thromboembolism, but the clinical relevance remains limited, because direct oral anticoagulants are more effective. Laboratory studies suggest that a twice-daily dosing regimen or evening intake may lead to more efficient platelet inhibition, and the potential clinical benefit of such strategies is currently being explored in ongoing clinical trials. Enteric-coated formulations of aspirin are frequently used, but it remains unclear if they are safer and as efficient as plain aspirin. In the future, aspirin use after percutaneous coronary interventions might not be mandatory in patients who also need anticoagulant therapy, as several trials support shorter aspirin duration strategies. On the other hand, new treatment indications for aspirin will likely arise, as there is growing evidence that aspirin may reduce the risk of colorectal cancer and other types of cancer.
No takes yet. Share an insight, caveat, or question.
Christiansen et al. (2021) studied this question. The provided text consists solely of the editorial board and publication information for Seminars in Thrombosis & Hemostasis, containing no clinical trial data or findings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: